Lausanne, July 23, 2009 - The FIVB Anti-doping Hearing Panel was in session in Lausanne on Wednesday for the hearing of the cases of Ms. Daniela Lanner Mapeli (Brazil) and Mr. Riley Salmon (USA).
The panel heard the players and made the following decisions:
The FIVB Anti-Doping Hearing Panel conclusions are as follows.
The player Daniela Lanner Mapeli (Brazil) has committed an anti-doping rule violation according to the FIVB Medical Regulations and the panel imposes on her a sanction of three-month suspension. The violation resulted from her taking the over-the-counter flu medication Gripefago C, which contains the prohibited substance isometheptene, during the CEV Women’s Final Four in Rome on March 14, 2009. The period of ineligibility started on July 22, 2009.
The player Riley Salmon (USA) has committed an anti-doping rule violation according to the FIVB Medical Regulations and the panel imposes on him a sanction of four-month suspension. The violation resulted from a miscommunication between the player and his physician regarding medication Mr. Salmon was taking as treatment for hypertension during an out-of-competition test taken on April 5, 2009, who was then training in Villorba (Italy) with his team Sisley Treviso. While his regular medication Avapro is allowed, the replacement drug Avalide contains the prohibited substance hydrochlorothizide. The period of ineligibility began on May 27, 2009, the date the athlete was provisionally suspended pending the hearing.
In a comment, the FIVB Medical Commission President, Dr. Roald Bahr, stated that although any violation of the anti-doping regulations must be taken seriously, none of these cases resulted from intentional doping.